Welcome to UroGen®
UroGen has a steadfast commitment to elevating options for people living with urological cancers. With breakthrough technology we are able to break barriers to treatment, pioneering a future of new possibilities in transformative therapies.
Innovation that
champions patients
Possibilities
brought to life
Our story
is dynamic
Explore UroGen news
Jun 17, 2024
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
about UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
Jun 17, 2024
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
about UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
Jun 13, 2024
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
about UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
Jun 7, 2024
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
about UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 6, 2024
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
about UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
Jun 5, 2024
UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
about UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
Jun 3, 2024
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
about UroGen Pharma Appoints David Lin as New Chief Commercial Officer
May 22, 2024
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
about UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
May 13, 2024
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
about UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
May 7, 2024
UroGen Pharma to Participate at Upcoming Investor Conferences
about UroGen Pharma to Participate at Upcoming Investor Conferences